723 related articles for article (PubMed ID: 24165127)
21. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
Lynch AM; Pathak N; Pathak V; O'Harte FP; Flatt PR; Irwin N; Gault VA
Diabetologia; 2014 Sep; 57(9):1927-36. PubMed ID: 24962667
[TBL] [Abstract][Full Text] [Related]
22. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
23. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.
Bossart M; Wagner M; Elvert R; Evers A; Hübschle T; Kloeckener T; Lorenz K; Moessinger C; Eriksson O; Velikyan I; Pierrou S; Johansson L; Dietert G; Dietz-Baum Y; Kissner T; Nowotny I; Einig C; Jan C; Rharbaoui F; Gassenhuber J; Prochnow HP; Agueusop I; Porksen N; Smith WB; Nitsche A; Konkar A
Cell Metab; 2022 Jan; 34(1):59-74.e10. PubMed ID: 34932984
[TBL] [Abstract][Full Text] [Related]
24. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.
Cui J; Shang A; Wang W; Chen W
Life Sci; 2020 Nov; 260():118339. PubMed ID: 32841660
[TBL] [Abstract][Full Text] [Related]
25. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
26. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
Jiao JJ; Hölscher C; Li T; Dong XF; Qu XS; Cao Y; Wu MN; Wang ZJ; Qi JS
Sheng Li Xue Bao; 2017 Apr; 69(2):135-145. PubMed ID: 28435972
[TBL] [Abstract][Full Text] [Related]
27. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
28. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
29. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
31. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
32. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
34. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
[TBL] [Abstract][Full Text] [Related]
35. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo.
Nakamura T; Tanimoto H; Mizuno Y; Tsubamoto Y; Noda H
Diabetes Obes Metab; 2012 Jun; 14(6):511-7. PubMed ID: 22192426
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
38. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
40. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
Lamont BJ; Drucker DJ
Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
